This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
TEM Stock Rises on Launch of AI-Powered Health Concierge App
by Zacks Equity Research
Tempus AI announces the launch of olivia, an AI-enabled personal health concierge app designed to revolutionize patient care and engagement nationwide.
TEM Stock Declines Following Preliminary Q4 Sales Miss
by Zacks Equity Research
Tempus reports strong 2024 growth and unveils a bold 2025 outlook with 75% revenue growth and innovative diagnostics.
Tempus AI Stock Falls Despite Collaboration Announcement With Genialis
by Zacks Equity Research
TEM announces a collaboration with Genialis to develop new RNA-based algorithms across cancer types.
The Zacks Analyst Blog Highlights Tempus AI, iRhythm Technologies and SOPHiA GENETICS
by Zacks Equity Research
Tempus AI, iRhythm Technologies and SOPHiA GENETICS are part of the Zacks top Analyst Blog.
Tempus AI Stock Surges 23% in 6 Months: Should You Snap It Up Now?
by Urmimala Biswas
TEM's cutting-edge product lines and strategic plans are positioning it for long-term success.
5 Top AI-in-MedTech Stocks for Big Gains in 2025: MDT, BSX & More
by Indrajit Bandyopadhyay
Here we discuss five medical stocks - MDT, BSX, BDX, GEHC and TEM - incorporating AI in their workflows. These are likely to gain in 2025 as AI helps cut costs and improve patient care.
Tempus AI Stock Plunges 28.9% in Three Months: What's Next?
by Debanjana Dey
TEM is enhancing its offerings and expanding the breadth of products and services to improve patient care. However, macro challenges are likely to hurt its performance.
Will Ambry Genetics Acquisition Drive Tempus AI's Prospects?
by Zacks Equity Research
TEM acquires Ambry Genetics, expanding its testing portfolio and redefining precision medicine.
Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
TEM's third-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level.
Tempus Stock Up Following Collaboration Expansion in Oncology R&D
by Zacks Equity Research
TEM's latest expanded partnership is likely to leverage multimodal real-world datasets and biological model systems in oncology R&D.